About Us

LambdaGen Therapeutics is based on a proprietary genome engineering tool called LIGIT (Lambda (λ)-Integrase Genome Insertion Tool) that allows specific insertion of large multi-gene cassettes or DNA fragments at safe harbour sites in human genome, empowering us to propel our research and development efforts to develop innovative solutions in the field of cell and gene therapy.

Our Technology

LIGIT (Lambda-Integrase Genome Insertion Tool)

LIGIT is a non-viral technological advance in the form of a novel λ-integrase mediated site-specific recombination system that requires

  • delivery of target circular DNA vector and,
  • expression of λ-integrase in the form of plasmid/mRNA
  • to carry out site-specific integration into host genome.

    How does it work?

    Our Platforms based on LIGIT

    PLATFORM 1: Targeting specific endogenous site (s) in human genome

    This involves targeting of a specific endogenous site (s) naturally present in human genome, termed as att(H) (att site 1) with the target vector comprising of attL/P (att site 2) using λ-integrase.

    This has been validated in various cell lines including-

  • HEK293, Expi293F, HT1080 and,
  • Human pluripotent cells such as hESCs and iPSCs
  • Current focus - Engineering and manufacture of iPSC derived NK cells for cancer immunotherapy

    LambdaGen aim to develop an off-the-shelf and affordable multifunctional CAR-NK (m-CAR-NK) cells with functionally enhanced anti-tumor characteristics against B-cell lymphoma. Our strategy includes safe and seamless transgenesis of large DNA payloads with advanced Chimeric Antigen Receptors (CAR) designs including multiple antigen targets, key proliferation interleukins, killing signals into the genome of iPSCs to be differentiated into NK cells.

    This would create a renewable source of iPSC derived m-CAR-NK cells, which will provide simultaneous biological improvements- a) enhanced tumor specificity; b) avoid tumour immune escape; c) sustained proliferative signals; d) enhanced tumoricidal activity; e) unlimited safe source of m-CAR-NK cells.

    PLATFORM 2: Targeting artificial introduced landing pad site (s) in human genome

    This involves targeting of artificially introduced site (s) in host genome, termed as att(L/P) (att site 1) with the target vector comprising of attH (att site 2) using λ-integrase. This has been validated.

  • To create a master cell line for therapeutic protein(s) testing and production including- HEK293, Expi293F, Hela cells
  • To engineer of marine microalgae (see below in “PRODUCTS & SERVICES”)

  • Current focus - Engineering Expi293F (HEK293) with anti-PD1 for cancer immunotherapy

    Lambdagen’s strategy involves implantation of immuno-protected, encapsulated producer cell lines to achieve long-term therapeutic effects in patients. In this context, LIGIT has been utilized to target the artificial landing pad with light and heavy chains of PD1 antibodies for stable integration. Currently, we are at the stage of testing our encapsulated cells for in vivo studies in cancer mouse models to study tumor behavior, fibrosis, viability and level of production of antibodies.

    PLATFORM 3: Seamless vector production using engineered Escherichia coli (E. coli)

    A novel E. coli strain carrying a tightly regulated gene cassette for the expression of the lambda integrase variant has been generated to efficiently recombine plasmids inside E. coli to yield seamless vectors ranging in size between 500 bp and >10 kb. The DNA is then isolated and cleaved with restriction enzymes together with the highly active phage T5 exonuclease ultimately resulted in high yields of pure negatively supercoiled seamless vectors.

    Products & Services

    Customized Cell line Engineering

    Cell line engineering on the basis of LIGIT with large transgene constructs >10kb

    *Validated in 8 different human cell lines including hESCs

    Small and Large-scale Seamless Vector (Mini Circles) Production

    Small- and large-scale seamless vector/DNA minicircle production with novel functional attributes: We offer a versatile production pipeline that can yield large amounts of pure seamless supercoiled vectors ranging in size between < 0.5 kb and>13 kb for various applications. Our seamless vectors carry novel attributes for downstream targeted genome insertion using LIGIT in various species (e.g. human, microalgae) as well as improved transient transgene expression relevant, e.g., for DNA vaccine development.

    We offer both in-house seamless vector production and licensing of the production pipeline.

    Genome engineering of marine micro-algal cell bioreactors

    Our propriety integrase platform can help achieve safe and precise genetic engineering in marine microalgae for the controlled and stable expression of recombinant proteins of your choice from artificial genomic docking sites.

    Commercial Cell Lines

    A stable transgenic female hES cell line expressing an Undifferentiated Transcription Factor 1 (UTF1) gene-based pluripotency reporter cassette. UTF1 expression is widely known as one of the most reliable indicator of the pluripotent and even totipotent state in human and mouse cells. We have capitalized on this unique feature and generated this versatile hESC reporter line for various downstream applications.

    The selection cassette is constitutively expressed from the targeted genomic integration site on human chromosome #1.

    A stem cell-based reporter system which can easily be adapted for high-throughput compound screening for FSHD disease. A Dux4 target gene reporter was developed that responds to the presence of functional Dux4. Upon binding of Dux4 to the array of target sites in the reporter, fluorescent protein mNeon will be expressed. Drug screening can be performed within a 24-48 hours time window to identify molecules that either interfere with or enhance transcriptional reporter activation by Dux4.

    A Hela cell line carrying a single copy of an Artificial Docking site that can be targeted with high precision and efficiency with single or multigene constructs to allow for sustained and highly homogeneous transgene expression without selection pressure. An ideal platform for the screening of mutant protein libraries or the reliable comparison of mutant phenotypes.

    An Expi293 (HEK293) cell line carrying a single copy of an artificial Docking site that can be targeted with high precision and efficiency with single or multigene constructs to allow for sustained and highly homogeneous transgene expression without selection pressure. An ideal platform for a) Screening of mutant protein libraries or the reliable comparison of mutant phenotypes. b) Production of therapeutic proteins

    Our Pipeline

    A robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious and rare illness.

    Project Lead Generation Discovery Preclinical IND Clinical Trials
    iPSC derived NK cells for Cancer Immunotherapies

    Patents and Publications

    Patent Description Year of filing Owner Inventors
    A versatile landing pad platform for transgenesis in human cells using enhanced λ integrases 2022 NTU & LambdaGen Dr Asim Siddiqui, Prof. Peter Droge, Dr Harshyaa Makhija
    Sequence-specific transgenesis at a novel human genomic safe harbor site with enhanced phage lambda integrase 2022 NTU & A*STAR Dr Asim Siddiqui, Prof. Peter Droge, Dr Harshyaa Makhija and 3 others
    Multi-scale production of multi-purpose seamless DNA vectors by regulated expression of enhanced λ integrase in Escherichia coli. 2021 NTU Prof. Peter Droge and 2 others
    DNA Mini-circles for targeted human genome editing 2017 (Granted) NTU Prof. Peter Droge, Dr. Harshyaa Makhija
    Mutants of the Bacteriophage Lambda Integrase 2014 (Granted) A*STAR Prof. Peter Droge, Dr. Harshyaa Makhija and 6 others
    Sequence- specific DNA recombination in eukaryotic cells 2005 (Granted) Prof. Peter Droge Prof. Peter Droge



    Dr. Harshyaa Makhija

    Co-founder and CEO

    Prof. Peter Droge

    Chief Scientific Advisor

    Uday Deshpande

    Chief Business Development & Strategy Advisor

    Advisory Board

    Prof. Charles Cooney

    Scientific and Business Advisor

    Dr. Howard Califano

    Scientific, IP and Legal Advisor

    Scientific Collaborators

    Prof. Sanjeev Gupta

    Albert Einstein College of Medicine, NY (US)

    Prof. Francesco Dazzi

    King’s College (London)

    Prof. Farzin Farzaneh

    King’s College (London)

    Prof. Dario Campana

    National University of Singapore (Singapore)

    Dr. Farid Ghadessy

    p53 Lab, A*STAR (Singapore)


    Internship Opportunities

    Business intern(s)

    LambdaGen (based on a leading edge genome insertion platform technology) is looking for smart, motivated and aspiring candidates who are currently pursuing graduate school or undergrad or IB/A levels to apply for an internship with us. It is a unique opportunity for candidates to build their skills, experience and profile to advance their career in the field of Biotech, Medical profession, Business development and Investment Banking.

    • Ambitious and self-driven individual with high expectations of his/her personal growth and development.
    • Motivated individual with ‘Can do’ attitude.
    • Keen to learn.
    • Self-Starter.
    • Excellent verbal and written communication skills.
    How apply

    Please send your resume and cover letter at LambdaGen Therapeutics or write to info@lambdagentherapeutics.com.

    Only shortlisted candidates will be notified.

    Job openings

    Research Scientist

    We are seeking an experienced Research Scientist to develop chimeric antigen receptor (CAR) Natural Killer cell-based cancer immunotherapies using proprietary lambda-integrase genome engineering technology. The ideal candidate will assist in the design of targeted iPSC-derived NK cell therapies, provide subject matter expertise for the development of allogeneic cell therapies targeting hematopoietic malignancies, and guide the evaluation of candidate cellular therapies from proof of concept through pre-clinical studies.

    • Ph.D. in cellular and molecular biology, genetics, immunology or oncology related field.
    • Must have prior hands-on experience with standard molecular biology techniques including cloning, PCR, qRT-PCR, Western blots and mammalian cell culture.
    • Strong technical background with gene editing and embryonic stem cell culture.
    • Prior experience in developing CAR-based immunotherapies is highly desirable.
    • Experience with multiparametric flow cytometry.
    • In vivo mouse experimentation with cancer models is a plus.
    • Plan and execute experiments and analyze data independently and contribute to team science.
    • Strong organizational, data management, research report and manuscript preparation.
    How apply

    Please send your resume and cover letter at LambdaGen Therapeutics or write to info@lambdagentherapeutics.com.

    Only shortlisted candidates will be notified.

    Join Us


    We are actively looking for collaborators or partners to be a part of our research and development and product development journey.


    We are constantly looking for investment opportunities to propel our initiatives forward.

    Contact Us

    Use the form below to drop us an e-mail. Old-fashioned phone calls work too

    Lab Address

    Clinical Science Building, 11 Mandalay Rd, Singapore 308232

    Phone Number

    +659 085 0564